KR102979182B1 - 항종양 아스코르브산 에스테르 - Google Patents
항종양 아스코르브산 에스테르Info
- Publication number
- KR102979182B1 KR102979182B1 KR1020237012737A KR20237012737A KR102979182B1 KR 102979182 B1 KR102979182 B1 KR 102979182B1 KR 1020237012737 A KR1020237012737 A KR 1020237012737A KR 20237012737 A KR20237012737 A KR 20237012737A KR 102979182 B1 KR102979182 B1 KR 102979182B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- mixture
- esi
- mmol
- ethyl acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382804.1A EP3967684A1 (en) | 2020-09-14 | 2020-09-14 | Antitumoral ascorbic acid esters |
| EP20382804.1 | 2020-09-14 | ||
| PCT/EP2021/075104 WO2022053679A1 (en) | 2020-09-14 | 2021-09-13 | Antitumoral ascorbic acid esters |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20230088718A KR20230088718A (ko) | 2023-06-20 |
| KR102979182B1 true KR102979182B1 (ko) | 2026-06-19 |
Family
ID=72709280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237012737A Active KR102979182B1 (ko) | 2020-09-14 | 2021-09-13 | 항종양 아스코르브산 에스테르 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230278974A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3967684A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7805651B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102979182B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN116724028B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021339010A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3191119A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3006988T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002970A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022053679A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120882410A (zh) * | 2023-03-09 | 2025-10-31 | 至善生医股份有限公司 | 包含13-顺式视黄酸和抗坏血酸的缀合化合物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772402A (zh) | 2012-08-14 | 2012-11-14 | 中山大学 | 维生素c-布洛芬酯在制备脑靶向制剂中的应用及其制备方法 |
| WO2018026673A1 (en) | 2016-08-01 | 2018-02-08 | IC-MedTech Corp. | Ascorbic acid, quinone compound, and sodium glucose cotransporter inhibitor for treating cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2831395B2 (ja) * | 1989-09-12 | 1998-12-02 | ハリマ化成株式会社 | アスコルビン酸エステル |
| JP3781877B2 (ja) * | 1997-10-03 | 2006-05-31 | 株式会社ムック | アスコルビン酸誘導体またはその塩、および医薬 |
| CN101550119B (zh) * | 2009-05-11 | 2012-05-30 | 无锡宏瑞生物医药科技有限公司 | 芳基(乙)丙酸抗坏血酸酯,其制备方法及含有它们的药物 |
| JP2016104708A (ja) * | 2014-12-01 | 2016-06-09 | 参天製薬株式会社 | アスコルビン酸誘導体を含有する非水性注射剤及びデポ形成方法 |
| JP6588764B2 (ja) * | 2015-01-26 | 2019-10-09 | 章博 田井 | 抗腫瘍剤 |
| CN106139151A (zh) * | 2016-04-29 | 2016-11-23 | 陈西敬 | 抗坏血酸棕榈酰酯与抗肿瘤药物协同作用的药物组合物 |
-
2020
- 2020-09-14 EP EP20382804.1A patent/EP3967684A1/en not_active Withdrawn
-
2021
- 2021-09-13 JP JP2023515364A patent/JP7805651B2/ja active Active
- 2021-09-13 MX MX2023002970A patent/MX2023002970A/es unknown
- 2021-09-13 EP EP21777302.7A patent/EP4211123B1/en active Active
- 2021-09-13 US US18/043,620 patent/US20230278974A1/en active Pending
- 2021-09-13 KR KR1020237012737A patent/KR102979182B1/ko active Active
- 2021-09-13 CA CA3191119A patent/CA3191119A1/en active Pending
- 2021-09-13 CN CN202180062720.9A patent/CN116724028B/zh active Active
- 2021-09-13 AU AU2021339010A patent/AU2021339010A1/en active Pending
- 2021-09-13 WO PCT/EP2021/075104 patent/WO2022053679A1/en not_active Ceased
- 2021-09-13 ES ES21777302T patent/ES3006988T3/es active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772402A (zh) | 2012-08-14 | 2012-11-14 | 中山大学 | 维生素c-布洛芬酯在制备脑靶向制剂中的应用及其制备方法 |
| WO2018026673A1 (en) | 2016-08-01 | 2018-02-08 | IC-MedTech Corp. | Ascorbic acid, quinone compound, and sodium glucose cotransporter inhibitor for treating cancer |
Non-Patent Citations (1)
| Title |
|---|
| Functional Foods in Health and Disease, 2019, Vol.9, No.3, pp.180-204 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023541840A (ja) | 2023-10-04 |
| CN116724028B (zh) | 2025-07-08 |
| CN116724028A (zh) | 2023-09-08 |
| EP3967684A1 (en) | 2022-03-16 |
| JP7805651B2 (ja) | 2026-01-26 |
| EP4211123A1 (en) | 2023-07-19 |
| EP4211123B1 (en) | 2024-11-06 |
| CA3191119A1 (en) | 2022-03-17 |
| ES3006988T3 (en) | 2025-03-19 |
| WO2022053679A1 (en) | 2022-03-17 |
| EP4211123C0 (en) | 2024-11-06 |
| MX2023002970A (es) | 2023-05-15 |
| AU2021339010A1 (en) | 2023-03-23 |
| KR20230088718A (ko) | 2023-06-20 |
| US20230278974A1 (en) | 2023-09-07 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |